Due to uniquely ordered nanoporous structure and high surface area as well as large pore volume, mesoporous materials have exhibited excellent performance in both controlled drug delivery with sustained release profiles and formulation of poorly aqueous-soluble drugs with enhanced bioavailability. Compared with other bulk excipients, mesoporous materials could achieve a higher loading of active ingredients and a tunable drug release profile, as the high surface density of surface hydroxyl groups offered versatility to be functionalized. With drug molecules stored in nano sized channels, the pore openings could be modified using functional polymers or nano-valves performing as stimuli-responsive release devices and the drug release could be triggered by environmental changes or other external effects. In particular, mesoporous silica nanoparticles (MSN) have attracted much attention for application in functional target drug delivery to the cancer cell. The smart nanovehicles for drug delivery have showed obvious improvements in the therapeutic efficacy for tumor suppression as compared with conventional sustained release systems, although further progress is still needed for eventual clinical applications. Alternatively, unmodified mesoporous silica also exhibited feasible application for direct formulation of poorly water-soluble drugs to enhance dissolution rate, solubility and thus increase the bioavailability after administration. In summary, mesoporous materials offer great versatility that can be used both for on-demand oral and local drug delivery, and scientists are making great efforts to design and fabricate innovative drug delivery systems based on mesoporous drug carriers.
Introduction
Since Vallet-Regí and co-workers [1] reported that MCM-41 loaded ibuprofen could be sustained-released in 80 h, the utilization of mesoporous silica materials in medicinal formulations has attracted much attention to achieve effective drug delivery [2, 3] . The newly developed ordered mesoporous silica material, which has a regular pore size distribution that can be systematically controlled at a range of 2 to 50 nm, has opened up new possibilities in pharmaceutical applications [4] [5] [6] [7] [8] . Because of their stable mesoporous structures, uniform and tunable pore sizes, high silanol-containing surface areas and pore volumes, easily-modified surface properties, non-toxic nature, as well as good biocompatibility, mesoporous silica carriers have shown advantages over conventional drug carriers for desired drug delivery. The mesoporous silica is in amorphous form and is degradable in an aqueous solution, and thus problems related to the removal of the excipient materials from body after administration can be avoided. Moreover, surface functional mesoporous materials, especially nanoparticles and hollow spheres, exhibit advantages for applications in drug delivery and gene transfection carriers [9] .
Recently, much attention has been attracted for application of mesoporous materials as drug carriers for objective oriented drug delivery [10] . Due to the ordered mesoporous structure, sustained release could be achieved by controlling the drug molecules diffusion from pore channels. Furthermore, more attention has been moved to achieve the controlled drug release via surface modification of mesoporous drug carriers. Polymer incorporated mesoporous drug carriers enabled "smart" drug delivery with response to stimuli, such as changes in pH, temperature and biological environment. The particle size was found to influence the application of mesoporous materials in drug delivery. The microparticles of mesoporous materials are limited for oral delivery, as microparticles cannot serve as efficient carriers for gene transfection or carriers for intracellular drug delivery because mammalian cells cannot efficiently engulf large particles via endocytosis. In addition, mesoporous silica microspheres are within the size window of bacteria and could potentially trigger acute immune response in vivo. To overcome this limitation, mesoporous silica nanoparticles (MSN) attracted more attention and have been intensively investigated for targeted drug delivery to cancer cells [11] [12] [13] [14] [15] . MSNs possess attractive characteristic properties that are superior to other materials for drug delivery. The particle size of MSN is tunable at range of 30-500 nm, allowing a facile endocytosis by living animal without any significant cytotoxicity. The pore size can be controlled at 2-8 nm by using different soft templates and the pore structure can has 2-dimensional cylindrical structure or interconnecting structure. The large pore volume allows high loading of active ingredient in drug vehicles, in addition, both of the large internal and external surface of MSN can be modified and functionalized with different moieties. The functionalized MSNs with size-and shape-controllable pores can store pharmaceutical drugs and prevent their premature release and degradation before reaching their designated target. Both the nanoparticle size and surface grafted ligand enhanced the uptake by cancer cells, thus functionalized MSN can be utilized to improve the efficiency of anticancer drugs through increased accumulation in tumors. Once the MSN drug vehicles reach the cancer cells, the functionalized controlled release property responses to the biological environment and exhibited intracellular drug delivery. The biocompatible MSN drug carriers at the effective dosages with targeting properties have shown to effectively deliver anticancer drugs to tumors, and exhibit excellent tumor suppressing effects. Functionalized MSN drug carriers have achieved steady progress in these targeted drug delivery areas.
In this review, recent applications of mesoporous material as drug carriers for efficient drug delivery and formulation are summarized according to the functionality of mesoporous excipients. Compared with counterparts of free drugs, mesoporous drug carriers bestow the formulated drugs with improved properties of sustained release, stimuli responsive smart delivery, targeted delivery or multifunctional incorporation with florescent and magnetic properties, enabling the drug release to be traceable and for the targeted sites to be imaged. Moreover, mesoporous materials also showed high potential for applications in the formulation of poorly water-soluble drugs with enhanced dissolution rate and solubility.
Mesoporous Drug Carrier for Sustained Release

Diffusional Control
The earlier reported results indicated that mesoporous silica drug carriers controlled the drug release rate by diffusion control and the application of mesoporous silica for sustained release has been intensively investigated [1, 16, 17] . The pore structure was found to obviously affect the diffusion rate of drug molecules from matrix to medium [18] , and thus pore structure was manipulated to control the drug release profiles [19] . Lopez et al. [20] investigated controlled release by using mesoporous silica with different pore structures as drug carriers. Drug release kinetics showed two stages: a fast release at early stage dominated by the controlled release of the hydrocortisone stored in the macropores of the reservoir, followed by a slow-rate delivery was proposed to be controlled by the hydrocortisone diffusion through the nanopores. Recently, Shen et al. reported mesoporous silica nanoparticle-functionalized poly(methyl methacrylate) (PMMA)-based bone cement for effective antibiotics delivery [21] . As shown in Figure 1 , the drug release profile of the commercial antibiotic formulated bone cement was characterized by a sharp initial burst due to the elution of antibiotics on the surface and in the voids in the sub-layers. As the drug release was subsequently very limited, it did not allow for a long-term sustained delivery of antibiotics. In addition, only a small portion of the loaded antibiotics could be released and more than 90% may still be entrapped within the PMMA matrix, which did not serve its function to protect the surrounding tissues from infection. When PMMA-based bone cements were functionalized with mesoporous silica nanoparticles (MSN), which exhibited a rod-like morphology with particle size about 100~400 nm in length and 100 nm in diameter, a highly efficient and sustained release of antibiotics was enabled to reduce the risk of post-operative joint infection. To overcome the limited drug release of 5% for only one day with the current commercial-grade bone cements, a 8 wt.% MSN-formulated bone cement was able to increase the drug release efficiency by 14-fold and sustain the release for up to 80 days. The loaded MSN was suggested to build up an effective network of rod-shaped silica particles with uniformly arranged nanoporous channels, which was responsible for the effective drug diffusion and extended time-release to the external surfaces. To build up an effective diffusion network for the sustained release of antibiotics from bone cement matrix, the particle size of mesoporous silica was also found to be important in the formulation. When larger particle size of mesoporous silica at submicron and tens of micrometer scales were used, the number of particles was much less than that of MSN with the same content of silica by weight. The fewer mesoporous silica particles and less homogeneity of distribution of those larger particles failed to build up an effective diffusion network by particle-particle contact, thus the release profiles of antibiotics were far below that of antibiotic bone cement functionalized by MSN fillers. Moreover, MSN had no detrimental effect on the critical weight-bearing bending modulus and compression strength of the bone cement. In vitro assay test results showed a much sustained antibacterial effect and low cytotoxicity of MSN demonstrating the potential applicability of MSN-formulated bone cement, which suggested its suitability to be considered for preclinical investigations. Effect of MSN content on gentamicin release profile and compared with  commercial antibiotic Smartset GHV bone cement (B-1: 8.15% MSN, B-2: 5.44%MSN and B-3: 2.72%MSN). Ref [21] .
In addition to mesoporous silica, mesoporous bioactive glass microspheres (MBG-MS) were also used for sustained drug delivery [22] . Novel MBG-MSs with tunable SiO 2 -CaO-P 2 O 5 contents of up to 25 mol.% CaO, with a partially ordered mesostructure, regular spherical morphology, large specific surface area, and pore volume have been successfully synthesized by an combined approach of emulsification-solvent evaporation induced self-assembly. The novel MBG-MSs could act as carriers to hold high amounts of bisphosphonate drugs, and wellsustained releases were obtained. The release profiles of bisphosphonate from MBGsMSs showed a two stage release mechanism with an initial fast stage in about 9 h followed by a much more sustained one of up to 18 days or longer, and the release rate can be in some way tuned by the addition of CaO.
When unmodified mesoporous silica was used as drug carriers to control drug release through diffusion, the drug loaded tablet or composite matrix was usually not disintegrated during the dissolution test. Once the individual drug loaded mesoporous silica particles were dispersed in dissolution medium, sustained slow drug release became less efficient.
Drug-host Interaction Control
To achieve extended drug release, the large surface areas of mesoporous materials provided wide platform to be modified and create interaction with drug molecules. The development of surface functional mesoporous material has been intensively explored and is still a very active topic in recent years [23] [24] [25] . The surface functional sites with moderate interaction with drug molecules play a large role in controlling the drug release than pore size for diffusion [26] . Mesoporous silica has been reported to be modified by either inorganic or organic compounds to achieve sustained release of active pharmaceutical ingredients. Shen et al. [27] reported that the surface of SBA-15 modified with alkaline MgO created an affinity with acidic ibuprofen molecules and retarded the release rate from the mesoporous matrix. In addition, the release rate of ibuprofen could be modulated by varying the content of MgO, and was found to decrease with increasing amount of MgO on surface of SBA-15 submicron particles.
In comparison, organic functional material modified mesoporous material exhibited more versatility in achieving sustained drug release. By coating or grafting functional groups on mesoporous materials, it can be made feasible for the development of functionalized mesoporous material drug delivery vehicles and for controlled release of drugs over extended periods. By selecting organic groups and deploying systematic design and fabricate approaches, nanoporous materials having different adsorption capacities and release properties for many drug molecules can be achieved [28, 29] . Amino group modified mesoporous materials were intensively investigated for controlled release of small molecular acidic drugs. Lee et al. [30] reported that positively charge functionalized mesoporous silica nanoparticles could be used for controlled release of an anti-inflammatory drug. The positive surface charge was generated by incorporating trimethylammonium (TA) functional groups into the framework of MSN (MSN-TA) via direct co-condensation of a TA-silane and tetraethoxysilane (TEOS). The amounts of loading of both Orange II and sulfasalazine were increased with increasing positive charge densities resulting from the increasing number of TA groups. When these drug-loaded MSN-TA nanoparticles were placed in physiological buffer solution (pH 7.4), a partial negative surface charge on the MSN-TA was generated due to the deprotonation of silanol groups, and the strong electrostatic repulsion triggered a sustained release of the loaded molecules. Similarly, cationic polymer poly[bis(2-chloroethyl)ether-alt-1,3-bis[3-(dimethylamino)propyl]urea] grafting on mesoporous silica was also found to create positive charges and exhibited well-sustained release profiles for ibuprofen and catopril [31] . Dimethylsilyl (DMS) modified mesoporous silicas could also greatly retard the ibuprofen release rate [32] . Moreover, the ibuprofen release profiles could be well modulated by varying DMS modification levels and site-selective distribution of functional groups in mesoporous carriers. Recently, Gao et al. [33] studied bimodal mesoporous silicas functionalized with different level and species of the amino groups for adsorption and controlled release of aspirin. The post-grafting modification was performed through the weak chemical interaction or hydrogen bonding in between OH groups of the mesopore surface and 3-aminopropyltriethoxysilane (N-TES) or 3-(2-aminoethylamino) propyltrimethoxysilane (NN-TES). The results showed that N-TES groups with different amount and NN-TES groups were successfully incorporated onto the mesopore surface. Subsequently, the controlled aspirin delivery properties from the resulting modified mesoporous silica could be achieved. The aspirin adsorption experiments indicated that the adsorption capacities of modified mesoporous materials were improved with the increasing amount of N-TES groups, while the NN-TES functionalized samples showed higher adsorption capacity than N-TES modified samples with the same ratio of modification. The reason is that the interaction between the NN-TES groups and aspirin molecules is stronger than that between the N-TES groups and aspirin molecules. The in vitro tests exhibited that aspirin release behaviors mainly depended on the variation of the amount and species of the functional groups in mesoporous carries. According to the Korsmeyer-Peppas model, it is found that the kinetic release constant, k, reduced with an increasing amount of the amino groups on the mesopore surface of modified mesoporous silica, suggesting that the aspirin release rate from the pores of mesoporous silica was influenced directly by organic groups on the surface. In addition to surface modification, functional group bridged periodic mesoporous organosilicas were also developed and exhibited to be particularly suitable for adsorption and desorption of drugs and could be utilized for controlled drug delivery. Parambadath et al. [34] reported that N,N'-diureylenepiperazine-bridged periodic mesoporous organosilicas (PDPMOs) have been successfully synthesized through co-condensation of bissilylated N,N'-diureylenepiperazine (BPDU) and tetraethyl orthosilicate (TEOS), using a triblock copolymer (Pluronic P123) as a structure-directing agent in acidic conditions with various BPDU to TEOS ratios. It was found that the organic functionalities could be introduced at a maximum of 30 mol% in the wall structure of the diureylenepiperazine-bridged periodic mesoporous organosilica (PDPMO-30) with respect to the total silicon content. Due to the presence of hydrophilic urea moieties within the wall structure, the drug release profile from the functional drug carriers was strictly in a controlled manner for both captopril and 5-fluorouracil. The nature of the drug molecule and its interaction with the host matrix also play an important role in controlled release.
Polymer grafted or coated on mesoporous excipient also exhibited excellent properties for sustained drug delivery [35] . By grafting poly(tetrafluoroethylene) (PTFE) on mesoporous silica, a novel vascular prosthesis with long-lasting antithrombogenicity, heparinloaded mesoporous vascular prosthesis, was successfully prepared, with the slow and sustained release of heparin from mesoporous channels [36] . After immersion in PBS buffer solution for 20 days, PTFE-mesoporous-silica loaded heparin was still able to release enough amount of heparin with high bioactivity to inactivate thrombin, indicating a long-term superior anticoagulant performance. This heparin release system maintained the long-term bioactivity of heparin and improved blood compatibility of biomaterials in vitro, better hydrophilicity, high resistance to platelet adhesion and superior cytocompatibility in favour of endothelialization of vascular prosthesis. Recently, Zhu et al. [37] investigated PEGylated hollow mesoporous silica nanoparticles as potential drug delivery vehicles. Hollow mesoporous silica (HMS) nanoparticles with the diameter of ca. 100 nm were synthesized using the colloidal carbon spheres as templates, and HMS-PEG nanoparticles were successfully prepared by covalently grafting poly(oxyethylene)bis(amine) on amino-group modified HMS nanoparticles with p-phenylene diisothiocyanate (DITC) as a cross linker. Doxorubicin hydrochloride (DOX), an anticancer drug, was loaded into HMS-PEG nanoparticles, and the DOX-loaded HMS-PEG nanoparticles had a sustained release property in 72 hr, as shown in Figure 2 . Furthermore, the DOX-loaded HMS-PEG nanoparticles exhibited higher cytotoxicity than the DOX-loaded HMS nanoparticles against Hela and NIH3T3 cells. Moreover, Tang et al. [38] reported mesoporous silica nanoparticles grafted with 5,6-dihydroxyhexylsilane (DH-MSN) and coated with cholic acid-crosslinked poly(lactic acid) (CA-PLA-MSN) as controlled release drug carriers. The CA-PLA-MSN material was able to significantly delay the release of the drug in intestinal condition compared with gastric acid surroundings due to the fast decomposition rate of PLA in gastric acid. The enzyme pepsin could play a favourable obstructive role in both DH-MSN and CA-PLA-MSN systems to reduce release rate. Recently, Ehlert et al. [39] reported the application of mesoporous silica coatings for the tuneable controlled release of antibiotics from implants. The drug loading capacity of the unmodified mesoporous coatings was low but could be increased nearly ten-fold (to about 2 µg/ cm -2 of the macroscopic surface) by functionalizing the mesoporous surface with sulfonic acid groups. To achieve a controlled drug release over an extended time period, further coatings were applied. Covering the surface of the drug loaded mesoporous silica layer by dip-coating with bis(trimethoxysilyl)hexane resulted in an organosiloxane layer which retarded the release for up to 30 days. By an additional evaporation coating with dioctyltetramethyldisilazane, the release of ciprofloxacin was prolonged for up to 60 days to effectively prolong the effective antibacterial activity period. Antibacterial efficacy was shown for a clinically relevant period of up to ten days, using pathogenic biofilm-forming bacteria. These results suggest that the development of drug loaded mesoporous silica films as coatings on medical implants is a promising approach to prevent bacterial implant infections during the most critical time span after implantation.
In addition to mesoporous silica, mesoporous polymer microparticles were also evaluated as drug carrier for controlled delivery. Restani et al. [40] reported that mesoporous microbeads can be obtained by radical polymerization of biocompatible glycerol dimethacrylate (GDMA) in supercritical carbon dioxide. Low density microparticles with controlled size (1-3 µm) and homogeneous morphology were obtained by the addition of different stabilizers to the polymerization media. The microbeads were obtained in quantitative yield as white, dry powders directly from the reaction vessel possessing a pollenlike morphology. The ibuprofen impregnation into the PGDMA mesoporous microparticles led to high loadings (up to 120mg/g) and exhibited a controlled release profile. The double (H-bonding) interaction of ibuprofen with the carbonyl and the hydroxyl groups of the poly-GDMA network, along with the mesoporous structure of the Poly-GDMA microparticles played a substantial role for controlled drug release.
Smart On-demand Drug Delivery
In addition to sustained slow drug release, surface functionalization has also enabled these mesoporous scaffolds ideal for the design of nanodevices and smart "on-command" delivery applications. Smart drug delivery systems that respond to a range of stimuli, including pH or temperature, enzymes, and photo irradiation have recently been reported. The development of smart mesoporous drug delivery is among the most active topics in recent research.
pH-responsive drug delivery
pH-responsive drug delivery is especially important for oral delivery as pH changes along the gastric-intestine (GI) tract. The use of oral administration is the first priority for delivering drug molecules for colon-related diseases such as irritable bowel syndrome, Crohn's disease, ulcerative colitis, and colon cancer. For the purpose of pharmacotherapy, the delivery of drug molecules through the oral route can provide patient compliance, convenience, and increase the therapeutic efficacy. In the field of traditional medicine, it is difficult to be completely cured of intestinal disease because some of the ingested drug would be adsorbed or digested by stomach before it reaches intestine. Therefore, it is very important to develop controlled intestinal drug release systems. pH-sensitive coated tablets have been developed and based on the solubility of the coated pH-sensitive polymers at various pH values of the GI tract, which increases from the stomach (pH 1.0-3.0) to the small intestine (pH 6.5-7.0), and to the colon (pH 7.0-8.0). When the formulated drugs pass through the low pH of stomach fluid, the low solubility of the enteric coating shells can efficiently protect the drug core from dissociation. Furthermore, the high pH values of the colon can accelerate the release of the drug core through the increasing solubility of the coated shells. Recently, mesoporous silica with large surface areas, large pore volume, highly ordered pore structure, and adjustable pore sizes, mesoporous silica material can load and protect therapeutic drugs and further control the release of pre-loaded drug molecules. Hong et al. [41] reported smart nanocontainers with a mesoporous core and a pH-responsive shell for controlled uptake and release. pH sensitive poly(acrylicacid) (PAA) was grafted onto the exterior surface of mesoporous silica nanoparticles as a smart nanovalve by reversible addition-fragmentation chain transfer (RAFT). As shown in Figure 3 , the mesoporous core can serve as a nanocontainer for guest molecules while the pH-responsive PAA nanoshell can be reversibly opened and closed, triggered by pH, which can act as a nanovalve to regulate the loading and release of guest molecules from the mesoporous core. Recently, Cheng et al. [42] also designed a novel pH controllable release drug delivery system using a modification of mesoporous silica nanoparticle (MSN) surfaces with pH-sensitive trimethylammonium (TA) groups through a pH-sensitive hydrazone bond. The pHsensitive TA groups could efficiently increase the loading amounts of anionic drugs by a strong electrostatic attraction. After oral administration, the acidic pH of gastric juice could fully hydrolyze the TA-hydrazone bonds and further eliminate the positive charges of the TA groups from MSN surfaces. When the hydrolyzed complexes were further delivered to the colon's pH of 7-8, a rapid and complete release of adsorbed drugs was observed. Under the stomach low pH condition, only 15% of drug was released from MSN-hydrazone-TA during 4 h of gastric emptying times. Regarding the drug release in the stimulated environment of the colon (pH 7-8), rapid release could be observed (80% during another 4 h) and no drug remained in excipient. In addition, a cell viability assay also indicated that no cytotoxicity of MSN-hydrazone-TA complexes was observed even with treatment in an extremely high nanoparticle concentration. Thus, this new formulation was highly biocompatible for oral drug delivery, and it solved the problems of low stability, low solubility, and low drug bioavailability faced in the free form of drug molecules. Similarly, Jin et al. [ 43 ] studied mesoporous-type spherical hollow silica nanoparticles using a selfassembled alanine-based amphiphile as a template which was then functionalized with curcumin molecules attached to the internal surface of the nanostructure by covalent bonding. The release of curcumin was controlled by pH. The curcumin attached onto the internal surface of hollow mesoporous silica nanoparticles was efficiently released into the aqueous phase over 120 min at pH 10, while it was not released to medium at pH below 7. Liu and Du [44] investigated the pH-controlled release of supramolecular nanovalves of cucurbit [7] uril (CB [7] ) pseudorotaxanes based on mesoporous silica carrier. The encirclement of CB [7] onto the protonated 1,4-butanediamine stalks anchored on the MCM-41 surfaces led to the tight closing of nanopores. The closed pores could be activated by the methods of deprotonation and competitive binding in aqueous media, so that the entrapped model molecules calcein were released from mesopores into bulk solutions. The increase of pH resulted in the deprotonation of the initially protonated 1,4-butanediamine units and the dissociation of the supramolecular complexes. The amount of released calcein increased with increasing pH. Cetyltrimethylammonium bromide (CTAB) and 1,6-hexanediamine could activate the nanovalves at near neutral pH through the shift of the supramolecular complex equilibrium. The increases in binding affinity and concentration of the competitors resulted in the increases of release rate and efficiency. Both of the methods could facilitate the nanovalves to realize controlled release on demand. On the other hand, mesoporous materials were functionalized using biomolecules as pore-blocking species for controlled-release of drug molecules at mildly acidic conditions, while preventing drug release at higher pH conditions. This effort offers useful guidance to the practical use of mesoporous nanoparticles for in vivo biological applications, such as intracellular controlled release of anticancer drugs [45] . Recently, Rim et al. [46] reported pH-tunable calcium phosphate covered mesoporous silica nanocontainers for intracellular controlled release of guest drugs. As shown in Figure 4 . a novel silica mesoporous (Si-MP) carrier covered with pH controlled, absorbable calcium phosphate (CaP) nanocoatings as pore blockers that allow the facilitated release of entrapped drugs within acidifying intracellular compartments such as endosomes and lysosomes. The CaP coatings can hold the encapsulated anticancer drugs under extracellular conditions, whereas they can be dissolved within intracellular endosomes as nontoxic ions to initiate drug release within tumor cells. Mineral-coated Si-MPs may satisfy the major requirements for cancer chemotherapy with a high delivery efficiency as this drug delivery system had high structural stability in blood, exhibited minimized premature drug release, and could release drugs specifically within tumor cells. The in vivo efficacy of doxorubicin (DOX) loaded Si-MP-CaP was confirmed using xenograft models of MCF-7 human breast cancers. A single intratumoral administration of DOX-Si-MPCaP was found to be significantly more efficacious in tumor reduction than control groups including free DOX and DOX-Si-MP without CaP coating. Similarly, Muhammad et al. [47] applied acid-decomposable, luminescent ZnO quantum dots (QDs) to seal the nanopores of mesoporous silica nanoparticles (MSNs) in order to inhibit premature drug (doxorubicin) release. After internalization into HeLa cells, the ZnO QD lids were rapidly dissolved in the acidic intracellular compartments, and consequently, the loaded drug was released into the cytosol from the MSNs. The ZnO QDs functioned as a dual-purpose entity that not only acted as a lid but also had a synergistic antitumor effect on cancer cells. Lee et al. [ 48 ] also investigated intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics, such as DOX. The pH-sensitive linker was conjugated onto MSN nanochannels surfaces by hydrazone bonds. First, the nanochannels of MSN were modified with aldehyde groups through the postmodification of the MSN inner surface with triethoxysilylbutyraldehyde. Next, the aldehyde group was reacted with one hydrazide group of adipic acid dihydrazide to produce a reactive hydrazone bond. Another hydrazide group was further reacted with the ketone groups of doxorubicin to produce additional hydrazone bonds in doxorubicin conjugation. The pH-sensitive linkers, when loaded with drug, possessed two hydrazone bonds that were cleavable at endosomal pHs. In vitro studies confirmed that no discernable DOX was released at neutral pH. At the endosomal pH of 4.5, however, associated DOX molecules were cleaved from the MSN nanochannels, resulting in that acidic pH values could effectively trigger the release of doxorubicin. To enhance cellular uptake and minimize self-aggregation, the outermost surfaces of MSNs were modified with trimethylammonium (TA) groups that increase the nanoparticle surface charge. In vivo test indicated that TA-MSNhydrazone-DOX samples had higher anticancer activities than MSN-hydrazone-DOX samples, as more positively charged surfaces of TA-modified MSNs increased the efficiency of their uptake by cancer cells. Thus the release of only 200 ng of DOX (corresponding to a total release of doxorubicin) from TA-MSN-hydrazone-DOX resulted in rapid decline of cell viability to about 20%. Similar stratagem based on amino group-functionalized mesoporous materials to create a pH-responsive system by constructing a designable coordination bonding-based "NH 2 -metal-DOX" architecture in mesopores for potential applications in antitumor therapies has been reported [49] . Figure 4 . a) Synthetic route to Si-MP-UR: 1) APTES; 2) removal of cetyltrimethylammonium bromide, glutaraldehyde; 3) Jack bean urease (UR). b) Field-emission scanning electron microscopy image of Si-MP-UR. c) Schematic of surface CaP mineralization of DOX-loaded Si-MP-UR and triggered drug release under intracellular endo/lysosomal conditions. HAp=hydroxyapatite. Ref [46] .
Many researchers investigated pH sensitive polymer coating or grafting mesoporous materials for pH controlled "on-demand" drug delivery. Yuan et al. [50] grafted poly(acrylic acid) onto mesoporous silica nanoparticles (PAA-MSNs) for controlled delivery of anti-cancer drug. DOX could be effectively loaded into the channels of PAA-MSNs through the electrostatic interaction. The loading content and the entrapment efficiency of DOX could reach up to 48% and 95%, respectively. The drug release rate of DOX@PAA-MSN was pH dependent and increased with the decrease of pH. The cumulative release amount of DOX could reach up to 70% after 24 h at pH 5.6, much higher than that at pHs 6.8 and 7.4, which was 42% and 13%, respectively. This is because with the decrease of pH more of the PAA was protonized, which would lead to the dissociation of electrostatic interaction between PAA and DOX, so that more of the incorporated DOX was released. The in vitro cytotoxicity test indicated that PAA-MSNs were highly biocompatible and suitable for use as drug carriers. The drug-loaded DOX@PAA-MSNs were distinctly cytotoxic to HeLa cells, due to the sustained release of drug, and showed higher clinical effects than free DOX. Similar pH sensitive DOX delivery were achieved by using chitosan/poly(methacrylic acid) coated on MSN [51] . Moreover, many kinds of pH-responsive polymer, such as poly(4-vinyl pyridine) [52] , polyelectrolytes [53, 54] , amphiphilic diblock polymer (poly(PDM-b-PEGMA)) [ 55 ] , hybrid poly(2-(diethylamino)ethyl methacrylate [56] coated mesoporous silica nanoparticles served as a switch to control the opening and closing of the pores. Release of guest drug molecules was conducted at different pHs, and the results showed rapid release in acidic aqueous solution but very little leakage in alkaline solution, exhibiting potential applications in sited release of anticancer drug and gene delivery. Moreover, a type of pH-responsive nano multi-drug delivery systems (nano-MDDSs) with uniform particle size and excellent monodispersity was developed by in situ co-self-assembly among water insoluble anti-cancer drug DOX, surfactant micelles (CTAB) as chemosensitiver and silicon species forming drugs/surfactant micelles-co-loaded mesoporous silica nanoparticles (drugs@-micelles@MSNs or DOX@CTAB@MSNs) via a micelleseMSNs self-assembly mechanism [ 57 ] . The nano-MDDS DOX@CTAB@MSNs demonstrated a highly pH-responsive controlled drug release behavior, in favor of precise intracellular drug release. A very small amount of DOX was released from DOX@CTAB@MSNs in a very slow dissolution at pH 7.4 PBS simulating normal physiological conditions, and only less than 2% of DOX was released after immersion for as long as 14 days which was indeed an extraordinarily low drug-released amount. When the pH values of release media decreased from 6.5 to 4 to simulate cancer conditions, both the DOX release rates and the DOX-released concentrations achieved remarkably higher. After immersion for 14 days, the DOXreleased percentage could reach about 26.6% in pH 4 release medium. The nano-MDDS DOX@CTAB@MSNs also exhibited high drug efficiencies against both drug-sensitive MCF-7 cells and drug resistant MCF-7/ADR cells by a synergistic cell cycle arrest/apoptosis-inducing effect between a poorly water-soluble anticancer drug and surfactant chemosensitizer.
Furthermore, the formulation of pH-responsive drug delivery has been developed as polymer coating onto mesoporous silica in tablet form [58] . pH-sensitive polymer hydroxypropyl methylcellulose phthalate (HPMCP) on famotidine-loaded mesoporous SBA-15 tablets enabled a pH controlled drug release system. In simulated gastric fluid (SGF, pH 1.2), it took only 2 h for famotidine to be completely released from mesoporous silica tablet without HPMCP coating. Also in SGF, with the increase of coating times and drying temperature, the release of famotidine was greatly delayed by HPMCP coating. However, in simulated intestinal fluid (SIF, pH 7.4), HPMCP coated tablet did not show any obvious effect on the release of famotidine. Xia et al. [59] developed mesoporous bioactive glass/polypeptide graft copolymer nanomicelle composites for pH-controlled dual-drug release. The dualdrug delivery systems were designed for simultaneous release of two different drugs; the release of each individual drug cannot be controlled. Hydrophilic gentamicin was loaded within the mesopores of the bioactive glasses and hydrophobic naproxen was encapsulated in the core of the polypeptide nanomicelles. The polypeptide nanomicelles were adsorbed on the surface of the mesoporous bioactive glasses through hydrogen bonds and the release of each individual drug was controlled by the pH of the surrounding environment. The hydrophilic gentamicin was quickly released from mesopores of MBG in acidic medium, while the hydrophobic naproxen was quickly released from the polypeptide nanomicelles in basic medium.
Temperature Responsive Drug Delivery
Among stimuli-responsive drug delivery systems, temperature-sensitive system have also attracted attention. The construction of thermo-sensitive delivery system was based on an organic-inorganic hybrid nanocomposite consisting of a temperature-responsive polymer and a mesoporous host. To date, temperaturecontrolled release of molecules from pore voids of mesoporous materials has mainly been achieved using a thermosensitive poly(N-isopropyl acrylamide) (P(N-iPAAm)) derivative, exhibiting volumetric expansion/contraction behaviour at 306 K, which can be used to develop a thermosensitive drug delivery system. de Sousa et al. [60] reported a facile and direct synthesis route to obtain hybrid functional nanosystems based on silica-P(N-iPAAm) by using a neutral surfactant and assessed the release rate of a model drug. The response of this hybrid system as a drug delivery device was influenced by volumetric contraction of P(N-iPAAm) up to the lower critical solution temperature (LCST) due to phase transition; above LCST, the drug release depends essentially on the temperature. Recently, Tian and Yang [61] reported that thermo-sensitive nanocomposites based on mesoporous silica SBA-15 and P(NiPAAm) have been synthesized via in situ radical polymerization in mesoporous structures. The resultant systems bring forth negative uptake and positive release behavior for model drug ibuprofen (IBU) in response to thermal stimuli from environment. A thermo-controlled sustained release and a switchable fast/slow release pattern can be realized by changing temperature around the LCST. At 25 o C, the release rate was lower; 300 minutes are needed to reach 80% of cumulative release of loaded ibuprofen. The release rate was much higher at 45 o C; the cumulative release achieved approximates 80% at 100 min of release time. It was expected that the release rate and the release percentage can be further modulated by modifying the relative sizes of the drug molecules and mesopore channels, the density of polymer network, the polymer content in composite and the interaction between drug and carrier. Furthermore, although most of the reported drug storage systems were based on mesoporous silica, mesoporous carbon was also used and functionalized with temperature responsive polymer P(N-iPAAm) for stimuli-responsive delivery [62] .
In addition to thermo-responsive polymers, Schlossbauer et al. [63] reported a programmable DNA-based molecular valve for colloidal mesoporous silica and exhibited thermo-responsive release of active ingredient molecules from pore channels of mesoporous silica. Biotin labeled DNA double strands were attached to the pore mouths of the core-shell mesoporous nanoparticles. This procedure allowed a subsequent closing of the pores by the protein avidin. The opening of the valve was achieved by DNA strand melting at the specific melting temperature of the oligonucleotide. At 25 o C, loaded guest molecules were not released due to closed control valves; while a burst release was observed at 45 o C. The nanodevices allowed the release temperature of theincorporated guest molecules to be adjusted precisely for a desired application. Recently, Aznar et al. [64] reported a new gated material that was based on the use of paraffins as capping molecules that can be melted at a defined temperature. As shown in Figure 5 , the mesoporous MCM-41 support loaded with a suitable guest (Safranine O), and the external surface was functionalized with octadecyltrimethoxysilane to give solid S1. These alkyl chains were not able to close the pores but are suitable to interact with paraffins through London forces; the paraffins set up a hydrophobic layer that could block the pores and inhibit guest release. An increase of the temperature above the paraffin melting point would result in melting of the paraffin and the subsequent uncapping of the pores, then loaded active ingredients could be released. The finely tuned tailor-made temperature triggered delivery achieved in these capped systems and the possibility to select a wide range of paraffins with specific melting points over a wide range of temperatures make these solids suitable for applications that demand zero release before stimulus implementation and render them important for delivery applications triggered by selected systemic or local temperature changes.
Overall, temperature responsive drug delivery system has not exhibited as much feasibility as that of pH-trigged drug delivery. Despite these reported examples, temperature-controlled release of molecules from mesoporous materials is still in its infancy, and there are no reported examples where the release temperature could be easily customized depending on target requirements. Moreover, the temperature of a warm-blooded animal is constant over the whole body, unless the temperature may be changed during an inflammatory period. Figure 5 . Representation of the gated materials S1-D, S1-H, and S1-T functionalized with octadecyltrimethoxysilane and capped with paraffin. Release profile of solids S1-H, S1-D, and S1-T at different temperatures. Release data were normalized to the maximum delivery obtained for each solid. Ref [64] .
Bio-responsive drug delivery
Despite many reported capping systems which are stimuli-responsive to pH or temperatures, there exists disadvantages such as the use of stimuli that are complicated and/or difficult to apply, poor applicability in aqueous solutions, poor biocompatibility, and the cytotoxicity of the capping agents used. Especially, given recent reports on capped mesoporous silica that can be interrupted by certain enzymes [ 65 ] or carbohydrates [ 66 ] , the application of mesoporous silica-based devices involving biomolecules for real delivery systems still have long way to go. Thus, the search for effective systems that, in particular, respond to internal biological stimuli still remains a big challenge in this field [67] . Recently, the application of using biomolecules (such as protein or DNA) as controlled gate responsive to stimuli of bioenvironment changes attracted researchers' attention to investigate [68] . Bernardos et al. [ 69 , 70 ] investigated the synthesis of a lactose-capped MSN that could be selectively uncapped using β-d-galactosidase by the rupture of a glycosidic bond. Enzyme β-d-galactosidase is a glycoside hydrolase involved in the hydrolysis of the disaccharide lactose into the monosaccharides galactose and glucose. The presence of the enzyme could induce cargo release of loaded guest molecules from the functionalized delivery system. Chen et al. [71] designed and constructed a stimuliresponsive vehicle for intracellular drug delivery using a polyvalent nucleic acid/MSN "click" conjugate that responded to both external and endogenous activation. The unique structural motif and self-recognition properties of duplex DNA, including temperature-dependent assembly, as well as the enzymatic recognition of specific encoded bases, could be applied as triggers for functional DNA manipulation. Selfcomplementary duplex DNA was anchored to the openings of the MSNs and was utilized as a cap for trapping the guest molecules within the the porous channels. Anticancer drugs camptothecin (CPT) and floxuridine (FUDR) successfully were loaded into functional MSNs, and efficient intracellular controlled drug delivery in human cancer cells when endogenous nuclease was used as a stimulus. Similarly, Coll et al. [72] anchored complex peptide sequences on mesoporous silica supports to develop nanodevices with zero release that were specifically opened in the presence of targeted proteolytic enzymes, as shown in Figure 6 . The MCM-41 support was loaded with a fluorescent dye [Ru(bipy) 3 ]Cl 2 ·6H 2 O, and the external surface was chemically modified with 3-(azidopropyl)triethoxysilane (solid S1). This azide group serves as a handle to attach the capping groups of a peptide sequence. P1 peptide attached to the azidefunctionalized MSN was able to hamper the release of the dye trapped in the pores, whereas delivery was triggered in the presence of a protease. dye from solid S1-P1 at pH 5 in the absence of protease enzyme. Ref [72] .
In addition to biomolecule capping gates, Zhu et al. [73] designed a novel and general bioresponsive controlled-release MSN capped with Au nanoparticles and could be triggered release by aptamer target interactions. The pores of the MSNs were capped with Au nanoparticles modified with aptamer (ATP). To examine the capping efficiency, the modified MSN-Au sample loaded with fluorescein isothiocyanate (FITC) was first dispersed in PBS solution without target molecules. The intensity of released FITC was essentially constant, indicating no obvious leakage of the entrapped dye molecules, whereas the uncapped MSN-FITC sample exhibited a rapid dye molecular transport. This result indicated that the capping strategy was successful with good efficiency. By a competitive displacement reaction, the Au nanoparticles were uncapped in the presence of ATP molecule, and the loaded guest molecules were released. In the presence of target molecules, the linkage between modified MSN and the Au-aptamer could be dissociated through a competitive displacement reaction, and the AuNPs would be uncapped from the drug release system. Therefore, it was expected that the release of FITC would be sensitive to the ATP molecule. About 80% of FITC release from the functional MSN-Au system was indeed observed in the presence of ATP molecules within 48 h. The results demonstrated that the aptamertarget interaction may be a promising route for the design of custom-made controlledrelease nanodevices specifically governed by target biomolecules.
The glucose-responsive controlled release of insulin is of great interest as it is a highly promising therapy approach to replace the frequent insulin injections for curing diabetes, which is an urgent medical challenge worldwide. Zhao et al. [66] report on the synthesis of a glucose-responsive MSN based double delivery system for both insulin and cyclic adenosine monophosphate (cAMP), which activates Ca 2+ channels of pancreas beta cells and hence stimulates insulin secretion with precise control over the sequence of release. As depicted in Figure 7 , gluconic acid-modified insulin (G-Ins) proteins were immobilized on the exterior surface of MSN and also serve as caps to encapsulate cAMP molecules inside the mesopores of MSN. The release of both G-Ins and cAMP from MSN could be triggered by the introduction of saccharides, such as glucose. Among different saccharide triggers, the release of FITC-G-Ins indeed showed a strong preference for fructose, followed by glucose. The release of FITC-G-Ins triggered by any of the saccharides was found to be completed within 30 min, which was within the time frame of normal insulin secretion. Recently, a novel glucose-responsive controlled release of insulin system was developed through coating enzyme multilayers on MSN [74] . The MSNs served as the drug reservoir, and the enzyme multilayers cross-linked with glutaraldehyde acted as a valve to control the release of insulin in response to the external glucose level. After insulin was stored into the MSPs via an immersion method, glucose oxidase enzyme and catalase were deposited onto the surfaces of the insulin stored MSN via glutaraldehyde cross-linking by means of the Schiff base reaction between the aldehyde groups on glutaraldehyde and the free amino groups on enzyme. Once contacted with glucose, glucose oxidase enzyme could convert glucose into gluconic acid, which decreased the pH value of the microenvironment around the particles and resulted in the volume expansion of the enzyme multilayer shells and the subsequent release of insulin from the pore system of MSNs. A near zero insulin release from the system under the absence of glucose was observed. It was found that the release rate could be well regulated by changing the glucose concentration, especially at a relatively low glucose level in the release medium. To test the repeated on/off effect, stepwise treatments of insulin regulatory release system alternatively with a glucose buffer solution (200 mg/mL) and a blank buffer solution every 1 h were performed. It was observed that after a burst of release in the first hour triggered by glucose, release stopped subsequently in a blank PBS, and then could be triggered again by glucose. Such a release on/off effect could be well repeated for at least 4 cycles. Thus this system combined the advantages of both high drug storage capacity and the glucoseresponsive controlled insulin release, and thus showed potentials for applications in diabetes therapy. 
Other-Responsive Drug Delivery
For efficient controlled release of toxic drugs in vitro and/or in vivo, it would be advantageous to design a capped MSN material that would respond to a noninvasive and externally controllable trigger, such as photoirradiation, or other physiological conditions. Vivero-Escoto et al. [ 75] reported a gold nanoparticlecapped MSN material for the photo-induced intracellular controlled release of an anticancer drug, paclitaxel, inside human fibroblast and liver cells. Gold nanoparticles were fuctionalized with a photoresponsive linker (thioundecyltetraethyleneglycolester-onitrobenzylethyldimethyl ammonium bromide, TUNA) and then capped the pore opening based on the electrostatic interaction between the positively charged gold nanoparticles and the negatively charged MSN materials. Fluorescein was loaded as a model guest molecule to test the photo-induced controlled release property. The fluorescein-loaded capped MSN sample was firstly stirred for 21 h before irradiation. Less than 0.003 μmol/g of fluorescein was leached into the aqueous solution, although 1.51 μmol/g of fluorescein was loaded. After the photo-induced controlled release of fluorescein was investigated at 365 nm under low-power (0.49 mW/cm 2 ) UV irradiation for 10 min, the release reached 100% after stirring in water for 35 h. A control experiment without UV irradiation was also carried out. No release of fluorescein was observed even after 80 h. The author also have demonstrated that pacliatxel molecules could be encapsulated inside of functional Au-MSN without the undesired drug leaching inside of live human fibroblast and liver cells and the release of anticancer drug was triggered by UV irradiation in 10 min. This "zero premature release" characteristic is of importance for delivery of toxic drugs in chemotherapy and cargo-release property easily controlled by low-power photo-irradiation under biocompatible and physiological condition, exhibiting potential as carrier materials for intracellular delivery of a variety of hydrophobic toxic drugs. Moreover, Lin et al. [ 76 ] found that functionalized mesoporous bioactive glasses (MBG) with photoactive coumarin demonstrates photoresponsive dimerization resulting in reversible gate operation. Irradiation with UV light (>310 nm) induced photo-dimerization of the coumarin-modified MBG, which led to the pores' closing with cyclobutane dimers and trapping of the guest phenanthrene in the mesopores. However, irradiating the dimerized-coumarinmodified MBG with shorter wavelength UV light (~250 nm) regenerated the coumarin monomer derivative by the photo-cleavage of cyclobutane dimers, such that trapped guest molecules could be released from the mesopores. The system demonstrated great potential in light-sensitive intelligent drug delivery systems and disease therapy field. In addition to UV responsive drug delivery, MSN-based nanocarriers with visible-light responsive drug delivery ability were also constructed to contain dendrimer molecules as caps [77] , nanoimpellers [78] , or functionalized by mercaptopropyl coordinated Ru(bpy) 2 (PPh 3 )-moieties [79] .
Ultrasound-triggered release has also been investigated to enhance the efficacy of loaded drug [80, 81] . Depan et al. [82] applied chitosan-mesoporous silica (CS-MS) hybrid composite to design a drug delivery system based on ultrasound triggered stimuli-responsive smart release. The results exhibited that ultrasound can be used as a non-invasive technique for drug release from polymeric materials. The enhancing effect of ultrasound on drug release was due to the Cavitation effect, without causing any significant destruction on the polymer morphology. Furthermore, intelligent drug delivery has also been investigated to be controlled by response to pressure pulse [83] , magnetic stimulus [84] and K + [85] .
Targeted or Local Delivery
Nanostructured materials, especially mesoporous or hollow nanoparticles, have been shown to play a propitious role in the noninvasive detection and treatment of tumors because of their unique characteristics inherent to the nanoscale [86] [87] [88] . Nanoparticles could be preferentially accumulated through passive targeting at the tumor sites or through the unique pathophysiology of tumors, such as their enhanced permeability and retention (EPR) effect and the tumor microenvironment. Moreover, by conjugation with tumor specific targeting ligands or antibodies, the functionalized drug vehicles can directly deliver anticancer drugs to selected tumor targets using active targeting strategies, thereby minimizing toxicity on normal cells. Surface modified nanoparticle drug vehicles with good biocompatibility avoid being identified as foreign objectives by the body and thus excreted before approaching the target tumor site. Although it is a great challenge of medicine technology to target delivery of drugs to tumor with defect cells, recent development with mesoporous silica nanoparticles as drug carriers highlighted promising progress for this objective [89] .
Ferries et al. [ 90 ] reported biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Transferrin and cyclic-RGD peptides were covalently attached to the nanoparticles. Transferrinmodified silica nanoparticles displayed enhancement in particle uptake by Panc-1 cancer cells over that of normal HFF cells. Moreover, by designing and attaching a synthetic cyclic-RGD, selectivity between primary cancer cells (BT-549) and metastatic cancer cells (MDA-MB 435) was achieved with enhanced particle uptake by the metastatic cancer cell line. These techniques exhibited the variety of different biomolecules to be integrated onto the nanoparticle surface for greater selectivity in various different types of cancer treatments. Incorporation of the hydrophobic drug camptothecin into these biomolecular-targeted nanoparticles led to an increase in mortality of the targeted cancer cells compared to that caused by both the free drug and non targeted particles. The results demonstrated successful biomolecular-targeted hydrophobic drug delivery carriers that selectively target specific cancer cells and resulted in enhanced drug delivery and cancer cell mortality. In addition, Luo et al. [91, 92] reported the fabrication of nano-reservoirs based on MSNs that were end-capped with collagen and demonstrated great potential for both cell-specific targeting and redox-responsive controlled drug release. Collagen, which is one of extracellular matrix (ECM) components, was employed as a cap to encapsulate fluorescent probes within the porous channels of the MSNs and was immobilized on the exterior surfaces of the MSNs by disulfide bonds. Lactobionic acid (LA), which bears a galactose group, was integrated to MSN as the targeting moiety to form a targeted drug delivery vehicle (LA-Col-MSN). The efficiency of the targeted delivery was investigated by the endocytosis and intracellular delivery of nanoparticles by HepaG2 and endothelial cells. The number of HepaG2 cells that internalized LA-Col-linker-MSN 2.2 times higher than that of endothelial cells after incubation for 4 hours, indicating the targeting property of LA-Col-linker-MSN to malign HepaG2 cells. The galactose groups on LA-Col-linker-MSN played an active role in facilitating a receptor mediated endocytosis and enhanced the uptake in cancer cells. The collagen endcapping enabled the feasibility of controlled drug release after being internalized by cancer cell, indicating collagen-capped LA-MSNs could serve as nanoreservoirs in a redox-responsive controlled release system for targeted drug delivery. Other ligands, such as folate, have also been grafted onto hollow mesoporous nanoparticles to enhance specific take up by Hela cells via receptor-mediated endocytosis and exhibited potential for targeted anticancer drug delivery [ 93 ] . Wang et al. [ 94 ] developed a novel delivery system comprising of a nanoscale PEGylatedphospholipid coating and 13-(chlorodimethylsilylmethyl)heptacosane-derivatized MSNs, in which therapeutic or imaging agents could be trapped and ligand-assisted targeted delivery may be achieved through surface functionalization of the phospholipids. A significant enhanced specific cellular uptake by Hela cells occurred after administering the folate-sensitized phospholipid-capped MSNs with targeting property. To increase the drug loading efficiency, hollow mesoporous silica (HMS) nanocages were developed for drug delivery to cancer cells to inhibit the growth of tumor [95] . As shown in Fig. 8 , empty HMS-PEG nanocages did not showed obvious difference from control group, implying that the drug carriers did not affect the tumor growth. However, due to an EPR effect, uniform and monodisperse PEG modified HMS nanocages loaded with DOX could reach and be taken up by the tumor cells and release drugs inside of the tumor cells, demonstrating a remarkable tumor growth inhibition efficacy of approximately 39.10% relative to control group, which is more effective than free DOX with an inhibition efficacy of about 22.33%. These results suggest that HMS nanocages are biocompatible and can effectively enhance the uptake of anticancer drugs and suppress tumor growth. Therefore, HMS nanocages possess the potential to make them a candidate for the research of particulate systems using in cancer therapy and drug delivery. In addition to mesoporous silica, monodispersed mesoporous cobalt ferrite nanoparticles were also investigated for applications in targeted delivery of antitumor drugs [96] . A folic acid decorated superparamagnetic mesoporous CoFe 2 O 4 based nanocarrier was synthesized and antitumor agents such as methotrexate and doxorubicin were successfully attached to the surface amine groups following simple organic coupling reactions. The drug loaded nanoparticle modified with folic acid effectively targeted cancer cells, thereby causing optimal delivery of methotrexate and resulted in cell death following the induction of apoptosis.
Another concept of targeted local drug delivery is associated with drug loaded biomaterials for tissue engineering. After drug formulated biomaterials were implanted, the controlled release active ingredients were preferentially absorbed at the local sites to prevent the post-operation infection or facilitate the regeneration of target tissues [21] . The mesoporous bioactive microspheres of SiO 2 -CaO-P 2 O 5 systems, for bone grafting and drug delivery has been investigated [ 97 ] . The mesoporous SiO 2 -CaO-P 2 O 5 microspheres exhibited bioactivity and developed an apatite like layer when reacting with simulated body fluid. Preliminary tests indicated the capability to load and release triclosan with kinetic profiles that depended on the pore structure, thus showing interesting features to be used in periodontal regenerative surgery and infection prevention. Similar research using SBA-15 and MCM-41 incorporated bioactive glass-ceramic scaffold for local drug delivery have been reported [98, 99] .
Multi-functional Drug Carrier
The large surface area and pore volumes as well as modifiable surfaces enabled functional MSNs loaded with large amounts of drugs and could be coupled to carry traceable (fluorescent or magnetically active) modalities, making them multifunctional drug carriers aimed at versatile applications. The functionalization of these mesoporous silica composites with magnetic property enabled them to be directed to the disease site under an external magnetic field, then followed by controlled release. To prevent the drug leaching during the transferring process, magnetic drug carriers were also modified with controlling gate or stimuli-responsive polymers. Furthermore, the fluorescent nanocomposite may target the path of delivery, thus supply the information about the mechanism of drugs delivery, and can be employed for qualitative and quantitative detection of disease position and drug release efficiency. The design and synthesis of fluorescent materials based on ordered mesoporous silica have great potential for imaging-guided therapy and has also attracted attention in recent research activity.
Magnetic Mesoporous Drug Delivery System
Mesostructured silica/magnetite nanocomposites appeared to be attractive drug carriers in the study of drug release systems with bioactive characteristics and the controlled drug release under an external alternating magnetic field. Magnetic nanoparticle drug carriers were usually fabricated by embedment into mesoporous silica in two steps: first, the monodispersed magnetite was synthesized, then the magnetic nanoparticles were coated with mesoporous silica using a nonionic block copolymer surfactants as structure-directing agents [100] . To improve drug loading, cavities between the magnetic nanoparticles and its surface was created [ 101 ] . Moreover, monodispersed mesoporous superparamagnetic single-crystal magnetites were also synthesized by solvothermal method and used for drug delivery [102] . Chen et al. [ 103 ] developed core/shell structured hollow magnetic mesoporous nanocapsules for simultaneous anticancer drug delivery and MRI cell imaging. The prepared multifunctional inorganic mesoporous nanocapsules showed both high loading capacity (20%) and efficiency (up to 100%) for DOX simultaneously because of the formation of the cavity, the enhanced surface area/pore volume, and the electrostatic interaction between DOX molecules and mesoporous silica surface. Besides, the capability of Fe, which is larger than that for the reported mesoporous silica nanoparticles decorated with magnetite nanocrystals. Therefore, the MSN@Fe 3 O 4 nanocarriers could perform well as T2-type MR contrast enhancement agents for cell or molecular imaging. The MSN@Fe 3 O 4 nanocarriers also demonstrated high cell uptake efficiency.
To achieve improved drug loading and controlled drug delivery, surface modification or functional polymers were conjugated with magnetic functional mesoporous materials to form mesoporous composites as drug carriers [104] . Chang et al. [105] achieved a higher loading content and M-MSNs-COOH presented a distinct pH-responsible release behavior. On the other hand, M-MSNs-Ph displayed a controlled release rate for a short term via the weakened hydrogen bonding interaction. These mesoporous nanoparticles were non-toxic to HeLa cells, while the drug-loaded nanoparticles apparently led to the unambiguous cytotoxicity as a result of the sustained release of anticancer drugs. When magnetic mesoporous silica nanoparticles were coated with thermal and pH responsive polymer poly(Nisopropylacrylamide-co-methacrylic acid) (P(NIPAM-co-MAA)), multi-functional controlled release of anticancer could be achieved [106, 107] . At physiological conditions (37 o C, 0.15 MNaCl), the P(NIPAMco-MAA) shell underwent a distinct transition from a swollen state at pH 7.4 to a collapsed state in pH 5.0, so that the polymer shell was active in moderating the diffusion of embedded drugs in-and-out of the pore channels of MSN. The cumulative in vitro release of the DOX-loaded composite microsphere showed a low level of leakage below the volume phase transition temperature (VPTT) and was significantly enhanced above its VPTT, exhibiting an apparent thermo/pH-response controlled drug release. Recently, Wu et al. [ 108 ] reported multifunctional rattle-type magnetic mesoporous silica (RMMSN) modified with a biocompatible polymer, poly(ethylene glycol) (PEG) and cancer-cell-specific ligand folic acid (FA) molecule modification with the aim of specifically targeting cancer cells, as indicated in Figure 9 . The assynthesized RMMSN-PEG/FA integrated magnetic and receptor-specific targeting effects, magnetic resonance imaging, and drug delivery into one. Combined Prussian blue staining, magnetic resonance imaging, and high-resolution sector field inductively coupled plasma-atomic emission spectroscopy (ICP-AES) analysis revealed that the obtained RMMSN-PEG/FA nanocomposite can specifically target cancer cells over-expressing FA receptors (FRs). The nanocomposites displayed very low in vitro toxicity and negligible hemolytic activity, which is in favor of further biological applications. Water-insoluble anticancer drug docetaxel was loaded into the surface-modified RMMSNs and delivered into human cancer cells via cell uptake. Surface conjugation with cancer specific targeting agent FA increased the uptake into cancer cells that over-express FRs. In addition, after intravenous injection, the RMMSN-PEG/FA nanocomposite could be transported to the designated organs directed by an external magnetic field. The inset in (a): typical SAED pattern of a hematite particle, and the inset in (f): single RMMSN-PEG/FA particle at a higher magnification. Ref [108] .
Apart from mesoporous silica, other mesoporous materials, such as mesoporous carbonated hydroxyapatite [ 109 ] , bioactive glass [ 110 ] were also functionalized with magnetic property. As hyperthermia has also been proposed as a potential therapeutic approach for bone defects resulting from malignant bone tumors, magnetic drug carriers attracted interest as it could result in local hyperthermia by an external electric-magnetic field. The multifunctionality of hydroxyapatite or bioactive glass scaffolds exhibited potential for their use in the treatment and regeneration of large-bone defects caused by malignant bone tumors through a combination of hyperthermia, local drug delivery and osteoconductivity.
Luminescent Mesoporous Drug Delivery System
Luminescence functionalized mesoporous silica particles can have potential in the fields of disease diagnosis, drug delivery and therapy. In addition to the high pore volume for storage and delivery, the presence of fluorescence properties enabled it to track and evaluate the efficiency of the drug release. The fluorescent nanocomposite enable to track the path of delivery, supply the information about the mechanism of drugs delivery, and can be employed for qualitative and quantitative detection of disease position and drug release efficiency. Therefore, the design, synthesis and application of fluorescent mesoporous nanocomposite for drug delivery also attracted great attention [111, 112] .
Huang et al. [ 113 ] reported a shell-by-shell synthesis of multi-shelled mesoporous silica nanospheres for optical imaging and drug delivery. The multishelled mesoporous nanostructures provided a platform for the development of a multifunctional vector by the inclusion of functional species into shell-to-shell cavities and porous shells. The encapsulation of the fluorophore and drug in shell-toshell space and mesoporous shells showed that multi-shelled silica spheres can be used in dual-modality for imaging and drug co-delivery vectors through the appropriate selection of pH-dependent molecules. The in vitro evaluation in tripleshelled silica indicated that an anti-cancer DOX, loaded in the outer periphery space, was successfully carried and released in the cytoplasm, then entered nuclei while fluorescein FITC (primarily distributed in inner periphery space) was effectively encapsulated inside the spheres. The double-and triple-shelled nanospheres consistently provided imaging probes with visible tracking capability in vitro and in vivo. Recently, Kang et al. [114] investigated core shell structured up-conversion luminescent and mesoporous NaYF4:Yb 3+ /Er 3+ @nSiO 2 @mSiO 2 nanospheres as carriers for drug delivery. The in vitro release study of IBU revealed a release profile in two steps: an initial diffusion-controlled release, followed by a slower release rate. Furthermore, upon excitation by a 980 nm near-infrared laser, the nanospheres emit green ( Figure 10 . Thus, the extent of drug release can be easily identified, tracked, and monitored based on the change of the up-conversion luminescence. in IBU-NaSiSi-0.15 as a function of the cumulatively released IBU. Ref [114] .
Moreover, luminescent mesoporous silica nanoparticles were recently reported to be fabricated by introduction of LaF 3 :Yb, Er cores [115] , oxygen-deficient sites [116] and lumingen [117] and their drug loading as well as delivery properties were also investigated. Fluorescent mesoporous nanocomposites incorporated with gold nanoparticles [118] and ATTO633-labeled cysteine linked to the inner particles [119] were used for controlled drug release and imaging of cancer cells.
In addition to mesoporous silica as a drug carrier, luminescent mesoporous hydroxyapatite has also been developed as multifunctional drug carriers. Zhang et al. [120] reported self-activated luminescent and mesoporous strontium hydroxyapatite nanorods for drug delivery. Strontium hydroxyapatite (SrHAp) nanorods with luminescent and mesoporous properties were synthesized by a facile hydrothermal method. The as-obtained SrHAp nanorods show an intense bright blue emission (centered at 432 nm, lifetime 11.6 ns, quantum efficiency: 22%), which might arise from CO 2 · -radical impurities in the crystal lattice under long-wavelength UV-light irradiation. The drug storage/release test indicated that the luminescent SrHAp nanorods showed a high drug loading and controlled release properties for ibuprofen (IBU). The emission intensity of SrHAp in the drug carrier system increased with the cumulative released amount of IBU, making the drug release to be easily tracked and monitored by the change of the luminescence intensity. Similarly, mesoporous silica/apatite composites also exhibited self-activated strong blue luminescence and could be used for controlled drug delivery [ 121 ] . Moreover, single-phased luminescent mesoporous lanthanide oxide nanoparticles that combined simultaneous drug delivery and cell imaging were investigated [122] . Wu et al. [123] reported that biocompatible, mesoporous titania nanoparticles were synthesized and further functionalized with a phosphate-containing fluorescent molecule and loaded with an anticancer drug (i.e. Doxorubicin) for successful intracellular bioimaging and drug delivery, respectively, in human breast cancer cells BT-20. The multifunctional drug carriers offered potential for applications in tumor diagnosing, and tracking the target drug delivery for chemotherapy.
Three-in-One Multifunctional Drug Delivery
Researchers have integrated multiple functions of magnetic property, florescence and controlled drug delivery in one system. Kim et al. [124] demonstrated the multifunctional bioapplications of the core-shell MSN for simultaneous magnetic resonance (MR) and fluorescence imaging, and for drug delivery. Monodispersed magnetic nanoparticles were coated with a layer of mesoporous silica for drug loading and release. For fluorescence imaging, fluorescein isothiocyanate (FITC) and rhodamine B isothiocyanate (RITC) were incorporated covalently into the silica walls by treating those dyes with 3-aminopropyltriethoxysilane and carrying out a subsequent silica sol-gel reaction. When the nanoparticles (NPs) with high colloidal stability under physiological conditions and size smaller than around 200 nm were injected intravenously, parts of NPs accumulate preferentially at tumor sites through their enhanced permeability and retention (EPR) effect in passive targeting. After 2 h of the intravenous injection, the accumulation of the NPs in tumors could be detected in the T2-weighted MR images. The strong fluorescence from the tumor was observed, representing the appreciable accumulation of the NPs in tumors through the EPR effect when investigated 24 h after the injection, while the accumulation in the rest of the organs, including liver and kidney, showed a typical accumulation. When the mesoporous silica layer was loaded with anticancer drugs, the multifunctional nanoparticles exhibited the potential for simultaneous diagnosis and therapy. Lee et al. [125] reported multifunctional mesoporous drug delivery system by decorating the surface of mesoporous dye-doped silica nanoparticles with multiple magnetite nanocrystals. The superparamagnetic property of the magnetite nanocrystals enabled the nanoparticles to be used as a contrast agent in magnetic resonance (MR) imaging, and the dye molecule in the silica framework imparted optical imaging modality. Integrating a multitude of magnetite nanocrystals on the silica surface resulted in remarkable enhancement of MR signal due to the synergistic magnetism. An anticancer drug, doxorubicin (DOX), was loaded in the pores and successfully delivered to the tumor sites and its anticancer activity was retained to effectively induce death of cancer cell. To maximize desired therapeutic responses, Lee et al. [ 126 ] developed multifunctional nanocomposite nanoparticles for simultaneous fluorescence and magnetic resonance (MR) imaging, and pH-sensitive drug release. The nanocomposites were fabricated by immobilizing pH responsive hydrazone bonds, magnetite nanoparticles and fluorescent dyes in mesoporous silica nanoparticles. pH dependent release of DOX was demonstrated and the nanocomposite nanoparticles show fluorescence emission and MR contrast effect.
To provide a versatile route for incorporating diverse functionalities into single composite nanoparticles, Chen et al. [127] reported a general polyelectrolytemediated self-assembly technique to prepare multifunctional mesoporous nanostructures as effective biological bimodal imaging probe and magnetically targeted anticancer drug delivery systems. A positively charged polyelectrolyte (PAH) and negatively charged fluorescent CdTe quantum dots (QDs) were successfully assembled onto the surface of ellipsoidal Fe 3 O 4 @SiO 2 @mSiO 2 composite nanostructures to combine the merits of tunable fluorescent/magnetic properties, mesoporous nanostructures for drug loading, and the uniform ellipsoidal morphology for enhanced uptake by cancer cells. The resultant nanoellipsoids were homogeneously coated with four layers of PAH/QDs, with an additional PAH layer to make the ellipsoidal surface positively charged. The created electrostatic interactions between the positive nanoparticle surface and the negative cell surface was believed to enhance cellular uptake. The excellent capability of the nanocarriers as contrast agents for MRI was demonstrated by preliminary in vivo characterization. To enhance drug loading in multifunctional drug delivery system, Wu et al. [ 128 ] recently developed a hollow core, magnetic, and mesoporous double-shell nanostructures (HMMNSs) via in situ decomposition and reduction of a -FeOOH nanorod core and organosilicate-incorporated silica-shell precursor. The fabricated HMMNSs were functionalized by silanization for further covalent conjugation to rhodamine B isothiocyanate (RBITC) and poly(ethylene glycol) (PEG) chains. The resultant RBITC-grafted and PEGylated nanocomposites (HMMNS-R/Ps) had excellent blood compatibility and very low cytotoxicity towards HeLa and MCF-7 cells, and could be taken up by cancer cells effectively in a dose-dependent manner, as confirmed by in vitro flow cytometry, confocal luminescence imaging, and magnetic resonance imaging (MRI) studies. Due to the large inner cavity of hollow core structure and enhanced surface area and pore volum, the HMMNS-R/P nanocomposites showed high loading capacity for water-insoluble anticancer drugs (docetaxel or camptothecin). The drug loaded nanocomposites also exhibited greater cytotoxicity than the corresponding free anticancer drugs. These results indicated that the multifunctional HMMNS-R/P nanocomposites are promising candidates for simultaneous bioimaging and therapeutic applications.
Mesoporous Recipients for Poorly Soluble Drug Formulation
The poor solubility of active pharmaceutical ingredients (APIs) in water is one of the most challenging issues in the development of many pharmaceutical products for commercialization. More than one third of the drugs listed in the US Pharmacopoeia and half of the new chemical entities (NCEs), or new active ingredients are poorly water soluble or insoluble. When these drugs are administered, they usually have a very low bio-availability because of their poor solubility in the digestive fluid, causing erratic and incomplete absorption that may lead to a loss in therapeutic effect. Many NCEs fail to be commercialized due to their insolubility or poor solubility in water. Much effort has been made to enhance the dissolution rate of poorly water-soluble drugs to increase bioavailability. Among various developments, producing drugs in the amorphous form is one of most promising approaches, as amorphous API possesses inherent property of high dissolution rate and improved solubility. Due to confined space of the ordered mesoporous channels, API loaded into mesoporous silica is preferably to be amorphous when the drug loading is below a certain limit. In recent years, the rapid dissolution of drugs from mesoporous silica has attracted research interest in the formulation of poorly water-soluble drugs to enhance the dissolution rate and bioavailability of such drugs [129] .
Poorly water-soluble drugs loaded onto unmodified mesoporous has been found to exhibit enhanced drug release rate. Loaded SBA-15 materials with pore sizes from 6.4 to 9.0 nm show the strongest enhancement of the release of itraconazole when compared to the dissolution of crystalline itraconazole itself [130, 131] . The original release behavior was maintained upon storage in dry conditions. Surprisingly, long-term storage at a relative humidity of 52% or 97% even had a beneficial effect on the release. Itraconazole phase analysis using DSC and analysis of the presence of itraconazole concentration gradients using XPS revealed that storage did not cause migration, aggregation or crystallization of itraconazole [132] . van Speybroeck et al. [133] reported a broad-spectrum formulation platform for poorly soluble drugs with mesoporous SBA-15 as an excipient. A series of 10 poorly soluble compounds with a high degree of physicochemical diversity (carbamazepine, cinnarizine, danazol, diazepam, fenofibrate, griseofulvin, indomethacin, ketoconazole, nifedipine, and phenylbutazone) have been investigated by using ordered mesoporous silicate SBA-15 as an excipient to enhance dissolution. All SBA-15 formulations exhibited an enhanced dissolution as compared to their corresponding crystalline materials, and the high pharmaceutical performance of all formulations was retained during the 6 months storage period. The results of this study suggest that encapsulation in SBA-15 can be applied as a dissolution-enhancing formulation approach for a very wide variety of poorly soluble drugs. Due to the enhanced dissolution, in vivo studies indicated that the extent of absorption of SBA-15 formulated drug was significantly higher than that of its counterpart commercial products, as the mesoporous formulation increased bioavailability [134, 135] . The effect of the pore structure and pore size on the dissolution performance of mesoporous silica loaded poorly soluble drugs was investigated. van Speybroeck et al. [ 136 ] investigated three ordered mesoporous silica materials with different pore diameters (7.3 nm, 4.4 nm and 2.7 nm) for the loading and release of a poorly soluble model drug (fenofibrate). The release experiments under sink conditions indicated a clear increase in the release rate with increasing pore size. Same trend was also found for mesoporous silica nanoparticles loaded poorly water-soluble drug telmisartan [ 137 ] . In addition to ordered 2D arranged mesoporous channels of SBA-15 and MCM-41, 3D cubic mesoporous silica microspheres were also developed for formulation of poorly soluble drugs to enhance their dissolution properties and bioavailability [138, 139] . Apart from mesoporous silica, the biocompatible mesoporous hydroxycarbonate apatite was also used as drug carriers to improve the dissolution rate and increase the bioavailability of poorly soluble drugs, intended to be administered orally [140] . It was found that the poorly soluble carvedilol loaded on mesoporous hydroxycarbonate apatite could also produce a burst release of carvedilol in comparison with micronized carvedilol in simulated gastric fluid and intestinal fluid. The amorphous form of carvedilol in the mesoporous carrier showed physical stability after room storage for 6 months.
Most of above reported poorly water-soluble drugs loaded onto mesoporous silica excipients were performed by impregnation and solvent evaporation. The drug loading procedure was found to affect the extent of improvement in dissolution property [141] . When drug loading was conducted by impregnation method, the amorphous formulation was limited to loadings of about 30%. The physical state of drugs was also found to be dependent on the drug loadings [142] . Crystalline form appeared if further increased drug loading. To increase the drug loading and produce solid dispersion formulations with mesoporous silica as excipient, Shen et al. [143] recently developed a co-spray drying process for the formulation of poorly watersoluble drugs to enhance dissolution properties. Ibuprofen (IBU) was selected as a model drug. With drug loadings of IBU/SBA-15 ratio being 50:50 (wt/wt) or below, most drug molecules were entrapped inside the straight mesoporous channels via the co-spray drying process and the morphology of the SBA-15 submicron particles remained unchanged. IBU confined inside the mesoporous structure was in the amorphous state as shown by PXRD and DSC measurements. The amorphous state of IBU in the solid dispersion showed remarkable stability when subjected to stress test condition of 40°C/75%RH in open pans for 12 months, as indicated in Figure 11 . The uniform pore walls were believed to prevent the re-crystallization of the homogeneously dispersed drug molecules inside the mesoporous channels with the confined nanospace. The dissolution rate of IBU from the co-spray dried solid dispersion was significantly enhanced to achieve a rapid release. Even after the accelerated stability test, the rapid drug release property was well preserved. These results indicated that by co-spray drying with mesoporous silica, stable amorphous solid dispersion with high drug loading could be achieved. The application of this formulation via spray drying could be extended to a wide range of poorly watersoluble compounds and drugs that can be dissolved in a suitable organic solvent to be formulated with mesoporous materials via co-spray drying. Figure 11 . XRD patterns of co-spray-dried IBU with mesoporous SBA-15 after storage at 40°C/75%RH for (a) fresh (b) 3 months, (c) 6 months, (d) 10 months, (e) 12 months; and (f) a control sample of commercial ibuprofen crystal. Ref [143] .
Moreover, the effects of pore sizes and particle sizes for this formulation were also investigated [144] .The particle size (ranging from about 150 nm to 20 µm) of SBA-15 only affected the dissolution of IBU slightly, where larger particle size excipients exhibited a slightly slower drug release due to the longer diffusion pathway. Amongst these mesoporous silica loaded IBU, the physical and solid state of ibuprofen were affected by pore size as drug molecules were entrapped inside the confined nano space of mesoporous channels. Nanocrystalline IBU could be formed inside pore channels equal to or larger than 20 nm, while IBU was amorphous in pore size smaller than 10 nm. The dissolution rate was found to be greatly affected by the solid state of ibuprofen. The amorphous IBU exhibited fast dissolution and the rate was weakly affected by pore size variation from 2 to 6 nm. As a comparison, the nanocrystalline IBU in the large pores of SBA-15-LP possessed a lower dissolution rate, even though the larger pore size could facilitate molecular diffusion from host matrix to medium. A similar trend was also found by van Speybroeck et al. [136] from the dissolution of fenofibrate formulated with mesoporous silica under supersaturating conditions, the pharmaceutical performance (in terms of both the degree and duration of supersaturation), increased with decreasing pore size, although the dissolution was increased with increasing pore size under sink conditions. Furthermore, the supersaturation generated from the immediate release of amorphous form of the API may cause precipitation and reduce bioavailability for absorption. To avoid precipitation of rapid released API from mesoporous silica solid dispersions, precipitation inhibitors hydroxypropylmethylcellulose (HPMC) was combined with ordered mesoporous silica for enhanced bioavailability and in vivo performance [145] . When high enough amounts of HPMC were co-administered with itraconazole-loaded SBA-15 (itraconazole:SBA-15:HPMC 1:4:6), the extent of absorption was increased by more than 60% when compared to SBA-15 without precipitation inhibitors (AUC 14,937 ± 1617 versus 8987 ± 2726 nM h). The results indicated that the pharmaceutical performance of mesoporous silica formulated poorly soluble drugs could be further improved by adding an appropriate precipitation inhibitor in combination administration.
The application of mesoporous silica as an excipient for the formulation of poorly soluble drugs is the most feasible approach for commercialization. This application addresses the pressing problems for pharmaceutical industries to improve dissolution rates, apparent solubility directly enhancing the absorption of dosed drugs. By improving the efficacy of the solid dosage form, the ultimate goal of reducing the amount of API required to deliver an adequate dose to the patient can be achieved. The formulation procedure is also feasible to be scaled for large scale production.
Summary
Research activity in the applications of ordered mesoporous materials for drug delivery and formulation has grown drastically over the last few years owing to the great versatility and stability of these mesoporous matrices. Modified mesoporous drug delivery system with response to stimuli allowed for "smart" drug delivery, where drug release could be controlled by changing pH, temperature or biological environment. In addition, new strategies could also be developed for site-specific nano-vehicles based on external triggers such as near infrared, magnetic field and ultrasound. Recent research focus has moved from sustained release to intracellular drug delivery, especially, to the area of applications of MSN for anticancer drug targeted delivery. Researchers intensively investigated the endocytic pathways for the enhanced uptake of modified MSNs with drugs, followed by the intracellular release. Florescent and/or magnetic incorporated MSN drug carriers enable multi-functional imaging, diagnosis and drug delivery. Although some ground breaking results exhibited that functionalized MSN nano-vehicles effectively delivered anticancer drugs to cancer cells and suppressed the growth of tumors, still more investigations are required for practical applications. To date, most of the reported MSN-based target-specific nano-vehicles obtained encouraging results in vitro, but few systems have been applied in vivo and therefore their complete success still has long way to go.
Another feasible application of mesoporous materials as an excipient for formulation of poorly water-soluble drugs has attracted great attention. It has been highly desirable to develop new formulations and methods that can amorphize an API to improve dissolution rates as well as stabilize the amorphous form during subsequent extended storage. Mesoporous silica materials could fully meet these requirements to enhance the bioavailability of poorly soluble drugs with the production process simple enough to have potential for industrial production.
